Arcus Biosciences(RCUS) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update • Data from the casdatifan 100 mg expansion cohort of ARC-20, a Phase 1/1b study in clear cell renal cell carcinoma (ccRCC), are expected to be presented at a medical conference in the fourth quarter of 2024 • PEAK-1, the initial Phase 3 study evaluating casdatifan in combination with cabozantinib, is expected to begin in the first half of 2025 • Patient enrollment has completed for the Phase 3 study ...